UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

| Filed by the Registrant ⊠ |
|--|
| Filed by a Party other than the Registrant □ |
| Check the appropriate box: |
| ☐ Preliminary Proxy Statement |
| ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ Definitive Proxy Statement |
| ☑ Definitive Additional Materials |
| ☐ Soliciting Material Pursuant to §240.14a-12 |
| Inhibikase Therapeutics, Inc. |
| (Name of Registrant as Specified In Its Charter) |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
| |
| Payment of Filing Fee (Check the appropriate box): ☑ No fee required. |
| ☐ Fee paid previously with preliminary materials. |
| \square Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| |
| |
| |
| |



INHIBIKASE THERAPEUTICS, INC.

2025 Annual Meeting Vote by June 26, 2025 11:59 PM ET



You invested in INHIBIKASE THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 27, 2025.

Get informed before you vote

View the Notice, Proxy Statement, and 2024 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 13, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number





Vote in Person at the Meeting*

June 27, 2025 4:00 PM EDT

https://web.lumiconnect.com/235841686 (password: inhibikase2025)

*If you choose to vote these shares in person at the meeting, you must request a "legal proxy." To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

INHIBIKASE THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 26, 2025 11:59 PM ET

| The election of two Class II diseases | Recommen |
|---|---|
| The election of two Class II directors | |
| Nominees: | |
| Amit Munshi | ⊘ For |
| David Canner, Ph.D. | ⊘ For |
| To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. | ⊘ For |
| To approve an amendment to the Company's 2020 Equity Incentive Plan to include an automatic "evergreen" provision and to extend the term of such plan. | ⊘ For |
| E: Such other business as may properly come before the meeting or any postponement or adjournment thereof. | |
| | |
| | David Canner, Ph.D. To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. To approve an amendment to the Company's 2020 Equity Incentive Plan to include an automatic "evergreen" |